Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization

New England Journal of Medicine

Volumn 342, Issue 18, 2000, Pages 1316-1324

  O'Neill, William W ^a   Serruys, Patrick ^b   Knudtson, Merrill ^c   Van Es, Gerrit Anne ^d   Timmis, Gerald C ^a   Van Der Zwaan, Coen ^b   Kleiman, Jay ^e   Gong, Jianjian ^e   Roecker, Ellen B ^f   Dreiling, Roger ^g   Alexander, John ^e   Anders, Robert ^e  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c FOOTHILLS HOSPITAL   (Canada)

^d CARDIALYSIS   (Netherlands)

^e PFIZER INC   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Oregon State University Oregon Health Science University College of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; XEMILOFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BENZAMIDINES; CORONARY ARTERY BYPASS; CORONARY DISEASE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STENTS; THROMBOCYTOPENIA;

EID: 0034604123     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200005043421803     Document Type: Article

References (42)

1. Fuster V, Adams PC, Badimon JJ, Chesebro JH. Platelet-inhibitor drugs' role in coronary artery disease. Prog Cardiovasc Dis 1987;29:325-46.
2. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36:4035-40.
3. Andrieux A, Hudry-Clergeon G, Ryckewaert J-J, et al. Amino acid sequences in fibrinogcn mediating its interaction with its platelet receptor, GPIIb/IIIa. J Biol Chem 1989;264:9258-65.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
5. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
6. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
7. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
8. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
9. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35. [Erratum, Lancet 1997;350:744.]
10. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995;91:2151-7.
11. The IMPACT-II Investigators, Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
12. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
13. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
14. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
15. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarc tion. N Engl J Med 1998;338:1488-97 [Erratum, N Engl J Med 1998; 339:415.]
16. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J Am Coll Cardiol 1999;33.634-9.
17. Carrozza JP, Baim DS. Thrombotic and hemorrhagic complications of stenting coronary arteries: incidence, management, and prevention. J Thromb Thrombolysis 1995;1:289-97.
18. Haude M, Erbel R, Issa H, et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 1993;126:15-22.
19. Ruygrok PN, Serruys PW. Intracoronary stenting: from concept to custom. Circulation 1996;94:882-90.
20. Hasdai D, Garratt KN, Holmes DR Jr, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996;28:361-7.
21. Fernández-Avilés F, Alonso JJ, Durán JM, et al. Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen. J Am Coll Cardiol 1996;27:22-9.
22. Mak K-H, Belli G, Ellis SG, Moliterno DL. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
23. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
24. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.
25. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
26. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-27.
27. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-4.
28. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following stenting. JAMA 1999;281:806-10.
29. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
30. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
31. Antoniucci D, Valenti R, Santoro GM, et al. Restenosis after coronary stenting in current clinical practice. Am Heart J 1998;135:510-8.
32. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-35.
33. O'Neill WW, Serruys P, Knudtson M, et al. Design and objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) study. J Interventional Cardiol 1999;12:109-15.
34. Ellis SG, Roubin GS, King SB III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-9.
35. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficiency, clinical safety, and outcomes after prolonged platelet glycoprotcin IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998;98:1268-78.
36. Antman EM, Braunwald E. Acute myocardial infarction. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:1352-65.
37. Gangnon R, Roecker E, Cook T. Sequential monitoring of multiple endpoints in clinical trials. Control Clin Trials 1999;20:35S. abstract.
38. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
39. Adgey AAJ. An overview of the results of clinical trials with glycoprotcin IIb/IIIa inhibitors. Eur Heart J 1998;19:Suppl D:D10-D21.
40. Dangas G, Marmur JD, King TE, et al. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 1999;138: 49-54.
41. Steiner B, Hofer U, Wittke B, et al. Plasma level of lamifiban and platelet receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A. Circulation 1998;98:Suppl I:I-561. abstract.
42. 3) inhibitors. Blood 1998;92:3240-9.